Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407990 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
A Phase 1 study of Advanced Cancer, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 451
- Enrollment target
- 20
- Study locations
NCT02407990 is a Phase 1 study of Advanced Cancer that has completed, run by BeiGene. The registered enrollment target is 451 participants, above the 243-participant average among 122 other Advanced Cancer trials with a reported enrollment target (86% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT02407990, a Phase 1 study of Advanced Cancer, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 451 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluated the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in participants with advanced tumors.
Conditions Studied
Interventions
- BIOLOGICAL BGB-A317
Study Locations (20)
Victoria
- Monash Health - Clayton
- Peter MacCallum Cancer Centre - East Melbourne
- Austin Health Hospital - Heidelberg
- Cabrini Hospital - Malvern
- Nucleus Network - Melbourne
- Royal Melbourne Hospital - Melbourne
Other
- Auckland City Hospital - Grafton
- Waikato - Hamilton
- Wellington Hospital - Wellington
- Seoul National University Hospital - Seoul
New South Wales
- Chris O'Brien Lifehouse - Camperdown
- Prince of Wales Hospital - Sydney
Queensland
- Tasman Oncology Research Ltd - Southport
- Princess Alexandra Hospital - Woolloongabba
South Australia
- Royal Adelaide Hospital - Adelaide
- The Queen Elizabeth Hospital - Woodville South
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- Oncology Consultants, P.A. - Houston
Western Australia
- Linear Clinical Research/Sir Charles Gairdner Hospital - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2020-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02407990
The ClinicalTrials.gov registry entry for NCT02407990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 451 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 243-participant average among 122 other Advanced Cancer trials with a reported enrollment target (86% higher). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which BGB-A317 is the first listed.
NCT02407990 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Victoria, Other, New South Wales.
Frequently Asked Questions
What is clinical trial NCT02407990 about?
NCT02407990 is a clinical study titled "Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors". This study evaluated the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in participants with advanced tumors.
What is the current status of trial NCT02407990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 451 participants. The study started on 2015-06-02. Estimated completion is 2020-08-12.
What conditions does trial NCT02407990 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT02407990?
The interventions under investigation include: BGB-A317 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02407990?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02407990 being conducted?
This trial has 20 study locations across Massachusetts, Texas, New South Wales, Queensland, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.